Immunome, Inc. (IMNM)

NASDAQ • Healthcare

$20.9

+$0 (+0.0%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$21.33

Day Range$20.82 - $21.46

Avg. Volume (3M)1.3M

Market Cap$1.9B

52 Week Range

$12.41$30.06

Next EarningsIn 32 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$254.3M

EPS (TTM)

-$2.54

ROA (TTM)

-44.98%

Current Ratio

15.08

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.8%Q3 2025-$0.5

-14.0%Q4 2025-$0.65

-27.1%Q1 2026-$0.75

+20.0%Q2 2026-$0.48

-26.5%Q3 2026-$0.65

Nov 5

in 32 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -26.5%

Immunome’s preliminary results for the second fiscal quarter of 2026 trailed expectations on EPS, with -$0.65 versus an estimate of -$0.51 (difference -$0.14), when it reported on August 11, 2026. The quarter’s GAAP net loss widened to about -$73.1 million, down 68.5% from about -$43.4 million a year ago, and operating income was about -$78.1 million as the company continued investing across its oncology pipeline, including antibody-drug conjugates and programs such as Varegacestat and IM-1021. On a per-share basis, EPS of -$0.65 compared with -$0.50 a year earlier (YoY -30.0%). Cash use remained elevated, with negative operating cash flow of roughly -$61.7 million. For the next period, consensus calls for EPS of -$0.64 on revenue of $181,818.00.

View full earnings history

About Immunome, Inc.

Immunome, Inc. (NASDAQ: IMNM) is a Biotechnology company in the healthcare sector developing oncology therapeutics in the United States. The company is a small-cap drug developer focused on antibody-drug conjugates and related cancer programs, with Varegacestat, IM-1021, and other pipeline assets spanning clinical and preclinical stages.

Name

Immunome, Inc.

CEO

Clay Siegall

Website

www.immunome.com

Industry

Healthcare

Year Founded

2006

Employees

247

Today's Snapshot

AI-generated

IMNM ended the day slightly higher at 20.90, in line with a flat sector. Immunome received clearance from the FDA, the U.S. drug regulator, to begin a Phase 1 trial of cancer drug IM-1340.

Trading Volume

Below 10d avg (1.5M)

1.1M

vs S&P 500 Today

Underperforming Market

-0.73%

Updated: October 2, 2026 at 20:22 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

IMNM exhibits pronounced bearish characteristics as price sits below near-term and long-term moving averages and momentum indicators are predominantly negative. MACD and CCI are bearish, the RSI is weak, and ADX above mid-20s indicates a significant downtrend rather than consolidation. Volatility is elevated for the share level with a relatively large ATR, and on-balance volume reflects selling pressure; pivots are marginally above current price and do not provide support. Technical takeaway: strong downside momentum, trend strength and selling volume align with a strong-sell assessment.

All signals